NMOSD acute attack: Understanding, treatment and innovative treatment prospect

Xiaoyu Ma; Allan G. Kermode; Xueqiang Hu; Wei Qiu

doi:10.1016/j.jneuroim.2020.577387

NMOSD acute attack: Understanding, treatment and innovative treatment prospect

Xiaoyu Ma
, Allan G. Kermode
, Xueqiang Hu
, Wei Qiu

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Review article › peer-review

41 Citations (Scopus)

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.

Original language	English
Article number	577387
Journal	Journal of Neuroimmunology
Volume	348
DOIs	https://doi.org/10.1016/j.jneuroim.2020.577387
Publication status	Published - 15 Nov 2020

Access to Document

10.1016/j.jneuroim.2020.577387

Cite this

@article{e1bef06edb7440f2882cf628a6078ec3,

title = "NMOSD acute attack: Understanding, treatment and innovative treatment prospect",

abstract = "Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.",

keywords = "Acute attack, Innovative treatment, Neuromyelitis optica spectrum disorder, Risk factor, Severe attack",

author = "Xiaoyu Ma and Kermode, \{Allan G.\} and Xueqiang Hu and Wei Qiu",

year = "2020",

month = nov,

day = "15",

doi = "10.1016/j.jneuroim.2020.577387",

language = "English",

volume = "348",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - NMOSD acute attack

T2 - Understanding, treatment and innovative treatment prospect

AU - Ma, Xiaoyu

AU - Kermode, Allan G.

AU - Hu, Xueqiang

AU - Qiu, Wei

PY - 2020/11/15

Y1 - 2020/11/15

N2 - Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.

AB - Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.

KW - Acute attack

KW - Innovative treatment

KW - Neuromyelitis optica spectrum disorder

KW - Risk factor

KW - Severe attack

UR - https://www.scopus.com/pages/publications/85091638899

U2 - 10.1016/j.jneuroim.2020.577387

DO - 10.1016/j.jneuroim.2020.577387

M3 - Review article

C2 - 32987231

AN - SCOPUS:85091638899

SN - 0165-5728

VL - 348

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 577387

ER -

NMOSD acute attack: Understanding, treatment and innovative treatment prospect

Abstract

Access to Document

Other files and links

Fingerprint

Cite this